NLA announces speaker lineup for upcoming scientific sessions
The National Lipid Association has announced the lineup of experts in lipidology that will address its scientific sessions, to be held May 19 to May 22 in New Orleans.
According to a press release from the association, a variety of topics in lipidology will be covered, from the use of nonstatin therapies to characteristics of apolipoprotein C-III (ApoC-III).
Use of nonstatin therapies
In one session, Carl E. Orringer, MD, FACC, FNLA, NLA president and associate professor of medicine at the University of Miami Miller School of Medicine, will discuss the recommendations from the new expert consensus statement from the American College of Cardiology on nonstatin therapies, of which he is an author.
Carl E. Orringer
FDA approval of two PCSK9 inhibitors in 2015 has expanded the options clinicians have to lower LDL in high-risk patients. Erik S. G. Stroes, MD, PhD, professor of medicine and chairman of the department of vascular medicine at Academic Medical Center, Amsterdam, and investigator on several PCSK9-related trials, including the recently presented GAUSS-3 study, will discuss a number of aspects of PCSK9 antibodies.
Erik S. G. Stroes
A presentation by Stanley Hazen, MD, PhD, section head of preventive cardiology and rehabilitation and chair of the department of cellular and molecular medicine at Cleveland Clinic, will cover how gut microbes can affect atherothrombotic heart disease.
“Our gut microbiome is a filter of our largest environmental exposure — what we eat — and functions fundamentally like an endocrine organ, producing differing levels of atherosclerosis-promoting metabolites depending upon what we feed it,” Hazen said in a press release.
Børge G. Nordestgaard, MD, DMSc, professor of genetic epidemiology at the University of Copenhagen, is slated to give a talk on lipoprotein(a) as a cause of CVD, while Anatol Kontush, BSc, PhD, research director at the research unit 1166 ICAN, National Institute of Health and Medical Research, Paris, will discuss new frontiers in HDL research.
In addition, W. Virgil Brown, MD, FNLA, Charles Howard Chandler Professor Emeritus, Emory University School of Medicine, Atlanta, is to give a presentation on the role played by hepatic endothelial lipase in the catabolism of very low density lipoprotein.
“This is a new area for important research in determining the relationship between ApoC-III concentrations and arteriosclerosis,” Brown said in the release.
The many roles of ApoC-III
Anne Tybjrg-Hansen, MD, DMSc, professor of clinical biochemistry at the University of Copenhagen, will give a keynote address on the pathophysiology of ApoC-III, as well as its roles as a risk factor and target.
The NLA also announced the recipients of several awards that will be presented at the sessions, including the W. Virgil Brown Distinguished Achievement Award to Joseph L. Witzum, MD, distinguished professor of medicine at the University of California, San Diego, and the NLA Honorary Lifetime Achievement Award to Jonathan C. Cohen, PhD, professor of internal medicine at Saint Louis University School of Medicine; Edward Fisher, MD, MPH, PhD, Leon H. Charney Professor of Cardiovascular Medicine and professor in the departments of medicine (cardiology), pediatrics (cardiology) and cell biology at NYU School of Medicine; and Helen Hobbs, MD, Dallas Heart Ball Chair in Cardiology Research, Philip O'Bryan Montgomery Jr., MD, Distinguished Chair in Developmental Biology and Eugene McDermott Distinguished Chair for the Study of Human Growth and Development at the University of Texas Southwestern Medical Center, Dallas.